title: [Intravitreal tissue plasminogen activator for treatment of central retinal vein occlusion associated with diabetic retinopathy].
abstract: OBJECTIVE
  To evaluate the effects of intravitreal injection of tissue plasminogen activator (tPA) on central retinal vein occlusion(CRVO) associated with diabetic retinopathy (DR).
  
  
  METHODS
  A retrospective study of 42 eyes of 42 patients(mean age: 68 years, female/male = 20/22, 5 eyes associated with DR) with macular edema caused by CRVO treated with tPA. Best corrected visual acuity (BVCA or logarithm of the minimal angle of resolution: logMAR), macular thickness was mea sured by optical coherence tomography (OCT), and several variables were evaluated.
  
  
  RESULTS
  The mean logMAR and macular thickness improved significantly in the DR (-) group, but, no significant changes were observed in the DR (+) group. Post-operative posterior vitreous detachment (PVD) developed in 62% of the DR (-) group and none of the DR (+) group.
  
  
  CONCLUSIONS
  There may be no beneficial effects of intravitreal tPA on CRVO associated with diabetic retinopathy.
authors.affiliation: Department of Ophthalmology & Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Japan kiyoshisuzuma@yahoo.co.jp
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Suzuma
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Murakami
authors.forename: Daisuke
authors.initials: D
authors.lastname: Watanabe
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Mihori
authors.initials: M
authors.lastname: Kita
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takagi
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D003930:Diabetic Retinopathy / Q000150:complications*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D014822:Vitreous Body
chemical_list: D010959:Tissue Plasminogen Activator